Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 534

The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update

Open access
Maurer, Marcus, Magerl, Markus, Betschel, Stephen, Aberer, Werner, Ansotegui, Ignacio J., Aygören‐Pürsün, Emel, Banerji, Aleena, Bara, Noémi‐Anna, Boccon‐Gibod, Isabelle, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik Balle, Brodszki, Nicholas, Busse, Paula J., Bygum, Anette, Caballero, Teresa, Cancian, Mauro, Castaldo, Anthony, Cohn, Danny M., Csuka, Dorottya, Farkas, Henriette, Gompels, Mark, Gower, Richard, Grumach, Anete S., Guidos‐Fogelbach, Guillermo, Hide, Michihiro, Kang, Hye‐Ryun, Kaplan, Allen Phillip, Katelaris, Constance, Kiani‐Alikhan, Sorena, Lei, Wei‐Te, Lockey, Richard, Longhurst, Hilary, Lumry, William R., MacGinnitie, Andrew, Malbran, Alejandro, Martinez Saguer, Inmaculada, Matta, Juan José, Nast, Alexander, Nguyen, Dinh, Nieto‐Martinez, Sandra A., Pawankar, Ruby, Peter, Jonathan, Porebski, Grzegorz, Prior, Nieves, Reshef, Avner, Riedl, Marc, Ritchie, Bruce, Rafique Sheikh, Farrukh, Smith, William B., Spaeth, Peter J., Stobiecki, Marcin, Toubi, Elias, Varga, Lilian Agnes, Weller, Karsten, Zanichelli, Andrea, Zhi, Yuxiang, Zuraw, Bruce, Craig, Timothy·2022·Allergy

Abstract

Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up‐to‐date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1 inhibitor (type 1) and HAE with dysfunctional C1 inhibitor (type 2), by providing guidance on common and important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on‐demand treatment and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast‐feeding women? and (5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/all.15214

Cites

170 of 170 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 534

Metadata

Authors
Maurer, M., Magerl, M., Betschel, S., Aberer, W., Ansotegui, I. J., Aygören‐Pürsün, E., Banerji, A., Bara, N., Boccon‐Gibod, I., Bork, K., Bouillet, L., Boysen, H. B., Brodszki, N., Busse, P. J., Bygum, A., Caballero, T., Cancian, M., Castaldo, A., Cohn, D. M., Csuka, D., Farkas, H., Gompels, M., Gower, R., Grumach, A. S., Guidos‐Fogelbach, G., Hide, M., Kang, H., Kaplan, A. P., Katelaris, C., Kiani‐Alikhan, S., Lei, W., Lockey, R., Longhurst, H., Lumry, W. R., MacGinnitie, A., Malbran, A., Martinez Saguer, I., Matta, J. J., Nast, A., Nguyen, D., Nieto‐Martinez, S. A., Pawankar, R., Peter, J., Porebski, G., Prior, N., Reshef, A., Riedl, M., Ritchie, B., Rafique Sheikh, F., Smith, W. B., Spaeth, P. J., Stobiecki, M., Toubi, E., Varga, L. A., Weller, K., Zanichelli, A., Zhi, Y., Zuraw, B., & Craig, T.
Venue
Allergy
Publisher
Wiley
Published
2022-02-03
Volume
77
Issue
7
Pages
1961-1990
ISSN
  • 0105-4538 (ISSN-L)
  • 1398-9995
OpenAlex
W4206038398
Cited by
534
References
170
FWCI
51.49
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.